Meeting
2023 ASCO Annual Meeting
Effect of tumor microenvironment on chemotherapy response of patients with triple-negative breast cancer receiving neoadjuvant chemotherapy.
Authors
Jae-Joon Kim
Pusan National University Yangsan Hospital, Yangsan-Si, South Korea
Jae-Joon Kim , Dongjin Kim , Yeuni Yu , Ki Sun Jung , Yun Hak Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 590)
DOI
10.1200/JCO.2023.41.16_suppl.590
Abstract #
590
Poster Bd #
420
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2024 ASCO Annual Meeting
Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer.
First Author: Jeeyeon Lee
Poster
2023 ASCO Annual Meeting
Association between genomic alterations and response of triple-negative breast cancers (TNBC) to talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy (NACT).
First Author: Hatem Hussein Soliman
Poster
2023 ASCO Annual Meeting
Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study.
First Author: Kun Wang